Page last updated: 2024-08-22

vidarabine and Arrhythmias, Cardiac

vidarabine has been researched along with Arrhythmias, Cardiac in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cai, W; Fujita, T; Hidaka, Y; Ishikawa, Y; Jin, H; Knollmann, BC; Okumura, S; Prajapati, R; Sato, M; Suita, K; Umemura, M; Yokoyama, U	1
Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY	1
Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E	1

Trials

1 trial(s) available for vidarabine and Arrhythmias, Cardiac

Article	Year
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leukemia & lymphoma, 2015, Volume: 56, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine	2015

Article

Year

An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.

Leukemia & lymphoma, 2015, Volume: 56, Issue:10

Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine

2015

Other Studies

2 other study(ies) available for vidarabine and Arrhythmias, Cardiac

Article	Year
Vidarabine, an anti-herpesvirus agent, prevents catecholamine-induced arrhythmias without adverse effect on heart function in mice. Pflugers Archiv : European journal of physiology, 2018, Volume: 470, Issue:6 Topics: Adenylyl Cyclase Inhibitors; Animals; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Calcium Signaling; Catecholamines; Heart; Herpesviridae; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Vidarabine	2018
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone marrow transplantation, 2010, Volume: 45, Issue:1 Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2010

Article

Year

Vidarabine, an anti-herpesvirus agent, prevents catecholamine-induced arrhythmias without adverse effect on heart function in mice.

Pflugers Archiv : European journal of physiology, 2018, Volume: 470, Issue:6

Topics: Adenylyl Cyclase Inhibitors; Animals; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Calcium Signaling; Catecholamines; Heart; Herpesviridae; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Vidarabine

2018

Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

Bone marrow transplantation, 2010, Volume: 45, Issue:1

Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2010